Sean Cassidy is the Chief Financial Officer of Arvinas, Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Sean has over 20 years of experience in the life sciences industry, including serving as Chief Financial Officer of Axerion Therapeutics, a preclinical biotechnology company developing therapies for neurological diseases and injuries; Chief Financial Officer of CuraGen Corporation, a clinical-stage biopharmaceutical company; and Director and Controller of 454 Life Sciences Corporation, a life sciences company that developed and commercialized next-generation DNA sequencing instruments and reagents. Earlier in his career, Mr. Cassidy served at Deloitte, one of the big four public accounting firms with a broad base of clients in the healthcare space. Mr. Cassidy is currently a board member of Oerth Bio, ReNetX Bio, and of the Friends of Yale New Haven Children’s Hospital, a nonprofit organization that helps improve the health and well-being of pediatric patients and their families. Mr. Cassidy holds an MBA and BS from the University of Connecticut and is a Certified Public Accountant in the State of Connecticut.